Prostate cancer and immunoproteome: Awakening and reprogramming the guardian angels

Archivum Immunologiae et Therapiae Experimentalis

Volumn 60, Issue 3, 2012, Pages 191-198

  Farooqi, Ammad Ahmad ^a   Fayyaz, Sundas ^a   Qureshi, Muhammad Zahid ^b   Rashid, Sadia ^c  

^a Rashid Latif Medical College RLMC   (Pakistan)

^b GC UNIVERSITY   (Pakistan)

^c NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

Author keywords

DNA damage; Immunoproteome; Major histocompatibility complex proteins; Prostate cancer

Indexed keywords

ATM PROTEIN; ATR PROTEIN; CANCER VACCINE; DNA VACCINE; GAMMA INTERFERON; IMMUNOPROTEOME; MAJOR HISTOCOMPATIBILITY ANTIGEN; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; ONCOLYTIC HERPES VIRUS; PEPTIDE VACCINE; PROSTATE STEM CELL ANTIGEN VACCINE; PROTEOME; STEAP[102-116] VACCINE; STEAP[192-206] VACCINE; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELL SURFACE; CELLULAR IMMUNITY; CYTOKINE RELEASE; DENDRITIC CELL; DNA REPAIR; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOPHARMACOLOGY; IMMUNOREGULATION; IMMUNOSELECTION; IMMUNOSUBVERSION; IMMUNOSURVEILLANCE; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; STANDARDIZATION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; DENDRITIC CELLS; DNA DAMAGE; GPI-LINKED PROTEINS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOTHERAPY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; MALE; MICE; MICE, TRANSGENIC; PROSTATIC NEOPLASMS; PROTEOME; RECEPTORS, NATURAL KILLER CELL; RNA INTERFERENCE; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 84863728588     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-012-0169-y     Document Type: Review

References (41)

1. Ardolino M, Zingoni A, Cerboni C et al (2011) DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction. Blood 117:4778-4786
2. Butler JE, Moore MB, Presnell SR et al (2009) Proteasome regulation of ULBP1 transcription. J Immunol 182:6600-6609
3. 2-microglobulin by pentameric IgM antibodies. Br J Haematol 154:111-121
4. Cerboni C, Zingoni A, Cippitelli M et al (2007) Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis. Blood 110:606-615 (Pubitemid 47105399)
5. Chakraborty M, Wansley EK, Carrasquillo JA et al (2008) The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res 14:4241-4249
6. Chávez-Blanco A, De la Cruz-Hernández E, Domínguez GI et al (2011) Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. Int J Oncol 39:1491-1499
7. Elkord E, Williams PE, Kynaston H et al (2005) Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer. Int Immunol 17:1315-1325 (Pubitemid 41488005)
8. Epel M, Carmi I, Soueid-Baumgarten S et al (2008) Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. Eur J Immunol 38:1706-1720
9. Fortmüller K, Alt K, Gierschner D et al (2011) Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody. Prostate 71:588-596
10. Fujii R, Iwahashi M, Kikkawa K et al (2009) Bacillus Calmette- Guérin cell-wall skeleton enhances the killing activity of cytotoxic lymphocyte-activated human dendritic cells transduced with the prostate-specific antigen gene. BJU Int 104:1766-1773
11. Garcia-Hernandez Mde L, Gray A, Hubby B et al (2008) Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 68:861-869 (Pubitemid 351206764)
12. Guerra N, Tan YX, Joncker NT et al (2008) NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28:571-580
13. Humphreys RE, Hillman GG, von Hofe E et al (2004) Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy. Cell Mol Immunol 1:180-185
14. Jachimowicz RD, Fracasso G, Yazaki PJ et al (2011) Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma. Mol Cancer Ther 10:1036-1045
15. Kandasamy M, Bay BH, Lee YK et al (2011) Lactobacilli secreting a tumor antigen and IL-15 activates neutrophils and dendritic cells and generates cytotoxic T lymphocytes against cancer cells. Cell Immunol 271:89-96
16. Kim S, Lee JB, Lee GK et al (2009) Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. Prostate 69:938-948
17. Klyushnenkova EN, Kouiavskaia DV, Berard CA et al (2009) Cutting edge: permissive MHC class II allele changes the pattern of antitumor immune response resulting in failure of tumor rejection. J Immunol 182:1242-1246
18. Kobayashi H, Nagato T, Sato K et al (2007) Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner. Cancer Res 67:5498-5504 (Pubitemid 46997291)
19. Kuang Y, Weng X, Liu X et al (2010) Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses. Cancer Lett 293: 254-262
20. Lemke CD, Graham JB, Lubaroff DM et al (2011) Development of an MHC class I L(d)-restricted PSA peptide-loaded tetramer for detection of PSA-specific CD8 ? T cells in the mouse. Prostate Cancer Prostatic Dis 14:118-121
21. Li H, Lakshmikanth T, Garofalo C et al (2011) Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell Cycle 10:3346-3358
22. Lu X, Ohata K, Kondo Y et al (2010) Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis. Cancer Sci 101:609-615
23. Mahadevan M, Liu Y, YouCet al (2007) Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus. Cancer Immunol Immunother 56:1615-1624 (Pubitemid 47094391)
24. Mitra N, Banda K, Altheide TK et al (2011) SIGLEC12, a humanspecific segregating (pseudo)gene, encodes a signaling molecule expressed in prostate carcinomas. J Biol Chem 286:23003-23011
25. Nanda NK, Birch L, Greenberg NM et al (2006) MHC class I and class II molecules are expressed in both human and mouse prostate tumor microenvironment. Prostate 66:1275-1284 (Pubitemid 44384304)
26. Ogbomo H, Michaelis M, Geiler J et al (2010) Tumor cells infected with oncolytic influenza A virus prime natural killer cells for lysis of resistant tumor cells. Med Microbiol Immunol 199:93-101
27. Pastor F, Kolonias D, McNamara JO II et al (2011) Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. Mol Ther 19:1878-1886
28. Raja Gabaglia C, Diaz de Durana Y, Graham FL et al (2007) Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors. Cancer Res 67:2290-2297 (Pubitemid 46424249)
29. Rodeberg DA, Nuss RA, Elsawa SF et al (2005) Recognition of sixtransmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. Clin Cancer Res 11:4545-4552 (Pubitemid 40825645)
30. Smith HA, Cronk RJ, Lang JM et al (2011) Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Res 71:6785-6795
31. Soriani A, Zingoni A, Cerboni C et al (2009) ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 113:3503-3511
32. Tabata K, Kurosaka S, Watanabe M et al (2011) Tumor growth and metastasis suppression by Glipr1 gene-modified macrophages in a metastatic prostate cancer model. Gene Ther 18:969-978
33. Tang KF, He CX, Zeng GL et al (2008a) Induction of MHC class I-related chain B (MICB) by 5-aza-20-deoxycytidine. Biochem Biophys Res Commun 370:578-583
34. Tang KF, Ren H, Cao J et al (2008b) Decreased dicer expression elicits DNA damage and up-regulation of MICA and MICB. J Cell Biol 182:233-239
35. Turkeri L, Onol FF, Ozyurek M (2010) Tumor specific cytotoxicity and telomerase down-regulation in prostate cancer by autologous dendritic cells loaded with whole tumor cell antigens. Urol Oncol 28:290-295
36. Varghese S, Rabkin SD, Liu R et al (2006) Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther 13:253-265 (Pubitemid 43255762)
37. Vittes GE, Harden EL, Ottensmeier CH et al (2011) DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen. Eur J Immunol 41:2447-2456
38. Waeckerle-Men Y, Uetz-von Allmen E, Fopp M et al (2006) Dendritic cell-based multi-epitope immunotherapy of hormonerefractory prostate carcinoma. Cancer Immunol Immunother 55:1524-1533 (Pubitemid 44327840)
39. Wu JD, Atteridge CL, Wang X et al (2009a) Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation. Clin Cancer Res 15:632-640
40. Wu JF, Zeng GL, Shen W et al (2009b) Up-regulation of major histocompatibility complex class I-related molecules A (MICA) induced by 5-aza-2′-deoxycytidine. Zhonghua Gan Zang Bing Za Zhi 17:675-678
41. Zhang X, Yu C, Zhao J et al (2007) Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8 + T-cell response and inhibits the PSCA ? tumors growth in mice. J Gene Med 9:715-726 (Pubitemid 47288829)